secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001628280-26-010377
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics appoints Ryan Maynard as CFO, replacing interim CFO Jeff Sacher
--------------------------------------------------------------------------------

- Ryan Maynard appointed CFO effective February 23, 2026; succeeds Jeff Sacher (interim CFO).
- Compensation: $510k base salary, 40% bonus target, $90k signing bonus, 400k share option grant.
- Maynard brings 25+ years experience; most recently CFO of Cara Therapeutics (2022-2025).
- Previously CFO at Rigel Pharmaceuticals, LetsGetChecked, and Blade Therapeutics; started career at Ernst & Young.
- Maynard raised over $1B in financings and executed reverse merger for Cara with Tvardi Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026010377/0001628280-26-010377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026010377/fhtx-20260223.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-010377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer